INNATE PHARMA (EPA:IPH) SIGNING OF A LIQUIDITY CONTRACT WITH GILBERT DUPONT ENDING OF THE PREVIOUS LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Transparency directive : regulatory news

03/09/2012 20:11

PRESS RELEASE

             SIGNING OF A LIQUIDITY CONTRACT WITH GILBERT DUPONT

              ENDING OF THE PREVIOUS LIQUIDITY CONTRACT WITH
                            NATIXIS SECURITIES

Marseilles, France, September 03, 2012

The liquidity contract signed on September 14, 2009 has been terminated by
INNATE PHARMA and NATIXIS. The termination is effective from August 31, 2012
after market.

As at August 31, 2012, the following assets appeared on the liquidity account:

  * 51,099 shares of Innate Pharma, and
  * 219,813.87 euros in cash.

INNATE PHARMA and GILBERT DUPONT signed on August 24, 2012 a new liquidity
contract in compliance with the AMAFI charter which will be effective on
September 4, 2012 before market.

For the implementation of this new liquidity contract, the following assets
appear on the liquidity account:

  * 51,099 shares of Innate Pharma, transferred from the previous liquidity
    contract, and
  * 219,813.87 euros in cash from the previous liquidity contract.

About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its innovative approach has been validated by licence agreements with
two major pharmaceutical companies, Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 81 employees as at
June 30, 2012.

Learn more about Innate Pharma at www.innate-pharma.com. Practical Information
about Innate Pharma shares:

ISIN code                FR0010331421
Ticker code              IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http ://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma                         ATCG Press
Laure-Hélène Mercier                  Marielle Bricman
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87           Mob.: +33 (0)6 26 94 18 53
investors@innate-pharma.com           mb@atcg-partners.com

120903 | Liquidity agreement update

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) SIGNING OF A LIQUIDITY CONTRACT WITH GILBERT DUPONT ENDING OF THE PREVIOUS LIQUIDITY CONTRACT WITH NATIXIS SECURITIES

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories